Prophylactic Doses of Tranexamic Acid (TXA) in Reducing Hemorrhagic Complications in bariatric surgery
EAES Academy. Lech P. 07/05/22; 363108; P153
CLICK HERE TO LOGIN
REGULAR CONTENT
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction
Laparoscopic sleeve gastrectomy (LSG) is currently the most common bariatric surgery in the world. Although it appears to be a safe treatment for obesity, it is still at risk of complications. The latest literature shows that postoperative bleeding occurs in 2-4% of cases, and up to 3% of cases requires reoperation for hemostasis. The aim of the study is to assess the effect of tranexamic acid (TXA) on hemorrhagic events and the reoperation rate in patients undergoing LSG.
Methods:
Comparison of two groups of patients 6 month prior and 6 month after bariatric surgery (after introducing the prophylaxis doses of TXA)
Results:
314 patients underwent LSG in a high-volume center from 2016 to 2017. After introducing TXA, a statistically significant reduction in the incidence of hemorrhage during surgery was observed (22.3% vs 10.8%, p=0.006). There was a statistically significant reduction in the need for the staple line oversewing (10.2% vs 1.9%, p=0.002). The mean operating time and the mean length of hospital stay were significantly higher in the non-TXA group than TXA group (63.1 vs 53.7 minutes, p<000.1; 2.3 vs 2.1, p=0.02). In both groups of patients, no venous thromboembolism or other complications occurred within 6 months after the surgery.
Conclusions:
The prophylactic doses of TXA can reduce the hemorrhagic complications in the early postoperative period after bariatrci surgery
Laparoscopic sleeve gastrectomy (LSG) is currently the most common bariatric surgery in the world. Although it appears to be a safe treatment for obesity, it is still at risk of complications. The latest literature shows that postoperative bleeding occurs in 2-4% of cases, and up to 3% of cases requires reoperation for hemostasis. The aim of the study is to assess the effect of tranexamic acid (TXA) on hemorrhagic events and the reoperation rate in patients undergoing LSG.
Methods:
Comparison of two groups of patients 6 month prior and 6 month after bariatric surgery (after introducing the prophylaxis doses of TXA)
Results:
314 patients underwent LSG in a high-volume center from 2016 to 2017. After introducing TXA, a statistically significant reduction in the incidence of hemorrhage during surgery was observed (22.3% vs 10.8%, p=0.006). There was a statistically significant reduction in the need for the staple line oversewing (10.2% vs 1.9%, p=0.002). The mean operating time and the mean length of hospital stay were significantly higher in the non-TXA group than TXA group (63.1 vs 53.7 minutes, p<000.1; 2.3 vs 2.1, p=0.02). In both groups of patients, no venous thromboembolism or other complications occurred within 6 months after the surgery.
Conclusions:
The prophylactic doses of TXA can reduce the hemorrhagic complications in the early postoperative period after bariatrci surgery
Introduction
Laparoscopic sleeve gastrectomy (LSG) is currently the most common bariatric surgery in the world. Although it appears to be a safe treatment for obesity, it is still at risk of complications. The latest literature shows that postoperative bleeding occurs in 2-4% of cases, and up to 3% of cases requires reoperation for hemostasis. The aim of the study is to assess the effect of tranexamic acid (TXA) on hemorrhagic events and the reoperation rate in patients undergoing LSG.
Methods:
Comparison of two groups of patients 6 month prior and 6 month after bariatric surgery (after introducing the prophylaxis doses of TXA)
Results:
314 patients underwent LSG in a high-volume center from 2016 to 2017. After introducing TXA, a statistically significant reduction in the incidence of hemorrhage during surgery was observed (22.3% vs 10.8%, p=0.006). There was a statistically significant reduction in the need for the staple line oversewing (10.2% vs 1.9%, p=0.002). The mean operating time and the mean length of hospital stay were significantly higher in the non-TXA group than TXA group (63.1 vs 53.7 minutes, p<000.1; 2.3 vs 2.1, p=0.02). In both groups of patients, no venous thromboembolism or other complications occurred within 6 months after the surgery.
Conclusions:
The prophylactic doses of TXA can reduce the hemorrhagic complications in the early postoperative period after bariatrci surgery
Laparoscopic sleeve gastrectomy (LSG) is currently the most common bariatric surgery in the world. Although it appears to be a safe treatment for obesity, it is still at risk of complications. The latest literature shows that postoperative bleeding occurs in 2-4% of cases, and up to 3% of cases requires reoperation for hemostasis. The aim of the study is to assess the effect of tranexamic acid (TXA) on hemorrhagic events and the reoperation rate in patients undergoing LSG.
Methods:
Comparison of two groups of patients 6 month prior and 6 month after bariatric surgery (after introducing the prophylaxis doses of TXA)
Results:
314 patients underwent LSG in a high-volume center from 2016 to 2017. After introducing TXA, a statistically significant reduction in the incidence of hemorrhage during surgery was observed (22.3% vs 10.8%, p=0.006). There was a statistically significant reduction in the need for the staple line oversewing (10.2% vs 1.9%, p=0.002). The mean operating time and the mean length of hospital stay were significantly higher in the non-TXA group than TXA group (63.1 vs 53.7 minutes, p<000.1; 2.3 vs 2.1, p=0.02). In both groups of patients, no venous thromboembolism or other complications occurred within 6 months after the surgery.
Conclusions:
The prophylactic doses of TXA can reduce the hemorrhagic complications in the early postoperative period after bariatrci surgery
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}